Years after the acute phase of the pandemic, many patients continue to live with cardiac symptoms that defy structural explanation — their hearts appear intact, yet function poorly, shadowed by inflammation and immune disruption. The Myoflame-19 trial, enrolling 279 people across multiple centers, tested whether a combination of losartan and prednisolone could quiet that inner fire and restore cardiac function. The primary measure — how well the heart's main chamber pumps — showed no meaningful improvement over placebo, a neutral result that does not close the story of post-COVID cardiac suffe
Nature
· Jul 30, 2026
· health
· 2 min de lectura
High
Verificación: Verificado
Post-COVID cardiac trial shows losartan-prednisolone combo fails primary endpoint
Persistent cardiac symptoms affect post-COVID patients, limiting physical function and quality of life despite absence of structural heart disease.
◉
Health & Medicine
9419 artículos relacionados
FDA Approves Pancreatic Cancer Drug That May Extend Patient Survival
CBS News · 100% coincidencia
Experimental pancreatic cancer drug daraxonrasib doubles survival in l…
USA TODAY · 99% coincidencia
Orillia's second deadly Legionnaires outbreak in three years kills one…
National Post · 99% coincidencia
'Walking Ebola' strain's slow progression complicates Congo outbreak r…
The Straits Times · 99% coincidencia
Uganda declares victory over Ebola as last patient discharged
BBC News · 99% coincidencia
Cobertura Relacionada
The Guardian · Sep 15
Key experts withdraw from Letby defence over scientific credibility concerns
Two leading scientists have quit Lucy Letby's defence team citing concerns about the scientific credibility of some argu…
News-Medical · Sep 15 Smartphone imaging shows 96% agreement with in-person cataract referrals in rural IndiaResearchers found 96% agreement between remote ophthalmologists reviewing smartphone images and in-person doctors for ca…
aip.org · Sep 15 Engineered heart tissue reveals fibroblast-cardiomyocyte crosstalk in hypertrophic cardiomyopathyResearchers using engineered micro-heart tissue discovered that communication between fibroblasts and cardiomyocytes is …
The Guardian · Sep 15 DRC Ebola outbreak peaks as daily cases decline from 120 to 80DRC authorities announce the Bundibugyo Ebola outbreak has peaked with daily cases dropping from 120 to 80, though nearl…
Sesgo y Encuadre
⚖
Nature reports neutral trial results objectively, acknowledging failed primary endpoint while noting safety and hypothesis-generating secondary findings without promotional language.
Bias Direction
center
Confidence
HIGH
Scientific neutrality with balanced presentation of negative primary outcome and exploratory secondary measures; structured around clinical trial methodology and statistical rigor.
Patient advocacy group perspectives on post-COVID cardiac treatment gaps
Commentary from clinicians treating post-COVID patients on trial implications
Industry/manufacturer perspective on future development plans
Health equity considerations for post-COVID populations
Impacto Geopolítico
🌎
Clinical trial failure has no geopolitical implications; this is a medical research article about post-COVID cardiac treatment efficacy, not a geopolitical event.
Escalation Risk
N/A
Confidence
HIGH
Lente Económico
📈
Failed clinical trial of losartan-prednisolone for post-COVID cardiac inflammation signals limited near-term commercial opportunity but informs future therapeutic development in underserved patient population.
Market Signal
bearish
Confidence
HIGH
Pharmaceutical/Biotechnology
Healthcare Services
Medical Devices (cardiac imaging)
Clinical Research/CROs
Post-COVID patients with cardiac symptoms lack effective targeted treatment options; trial failure delays potential therapeutic relief but safety data may enable alternative combination approaches or dosing strategies in future studies.
Regulatory agencies may require larger, longer-duration trials for post-COVID cardiac therapies; findings support FDA/EMA guidance on immunomodulation trial design; potential for accelerated approval pathways if secondary endpoints show promise in future studies with refined patient populations.